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Patients with type 2 diabetes mellitus (DM) have more disturbances of sexual and reproductive functions. The 
consequences of type 2 DM may include dyslipidemia, insulin resistance (IR), cardiovascular disease (CVD) and 
low testosterone level. The main objective of this study is to determine the value of various biochemical 
parameters in relation to erectile dysfunction (ED) in type 2 DM patients in Gaza city, Palestine. A total of 160 
males between the age of 35 – 60 years were recruited; 80 type 2 DM patients and 80 as controls. 
Anthropometric, demographic, sexual and clinical data were obtained by questionnaire. Increased prevalence 
of high BMI and HOMA-IR were observed among type 2 DM patients, while high incidence of low testosterone 
was found in the same group (p < 0.05). Testosterone was correlated negatively and significantly with BMI and 
duration of type 2 DM (p < 0.05). ED was correlated significantly and directionally with dyslipidemia, duration of 
type 2 DM, and complications of diabetes mainly retinopathy (p < 0.05). While, nocturnal/early morning erection 
(NEME) was correlated significantly but inversely with duration of type 2 DM (p < 0.05). In addition, fasting blood 
glucose (FBG), duration of type 2 DM and low level of testosterone were predictor factors associated with ED (p 
< 0.05), while increased BMI was a predictor factor associated with low testosterone level (p < 0.05). In the 
present study, high incidence of low testosterone and increased prevalence of ED among type 2 DM patients 
could be attributed to uncontrolled type 2 DM, obesity, IR, dyslipidemia, long duration of type 2 DM and its 
complications. 
 





Type 2 DM comprises an array of dysfunctions resulting 
from the combination of resistance to insulin action and  
inadequate insulin secretion. Its disorders are 
characterized by hyperglycemia and associated with 
microvascular, macrovascular, and neuropathic 
complications. It is a common disorder with a prevalence 
that rises markedly with increasing degree of obesity 
(Salem et al, 2011). One of the complications of type 2 
DM is the disturbance of sexual and reproductive 
functions. Low circulating testosterone concentration is 
frequently found in men with metabolic syndrome (MS) 
and type 2 DM (Arver, 2008 and Jones, 2008). ED is the 
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sufficient to permit satisfactory sexual performance (Al-
Adl et al., 2011). The inability to achieve and maintain an 
erection sufficient for satisfactory sexual intercourse is a 
distressing and common symptom, affecting up to one-
third of adult men. The prevalence of ED increases with 
age, and it is common in men with systemic disorders 
such as hypertension, ischemic heart disease, or DM  
(McCulloch, 2013). Among diabetic men, the prevalence 
varies from 35 to 90% (Giugliano, 2010). Many factors 
are associated with ED, among these are depression, 
hormonal changes, and vascular or neurologic damage 
after trauma or surgery. ED is also associated with 
different endocrine-metabolic disorders like type 2 DM, 
and dyslipidemia (Knoblovits et al., 2010). Whitsel et al. 
(2001) reported that testosterone reduced total 
cholesterol and Low density lipoprotein-cholesterol (LDL-
C), while   Roger   et   al.   (2007)   reported   a   positive  
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association between high density lipoprotein-cholesterol 
(HDL-C) and testosterone in men with type 2 DM. In 
addition, ED appears to arise about 10 years earlier in 
diabetic patients than in the general population, and 
decreases the health-related quality of life (Phe and 
Roubret, 2012). A study showed that hypogonadism is 
frequently associated with type 2 DM, at least in the 6th 
decade, type 2 DM associated with hypogonadism might 
exacerbate sexual dysfunction by reducing  libido and 
mood and further compromising penile vascular reactivity 
(Corona et al., 2006). Other researchers found a 
significantly lower concentrations of testosterone and 
HDL-C,   but higher concentrations of glucose in patients 
suffering from MS and type 2 DM compared with controls 
(p < 0.05). Testosterone correlated positively with libido 
and NEME but inversely with ED in type 2 DM (p < 0.05). 
Deficient  glucose uptake  by  the  pituitary  and the  
gonads  and  low  circulating  HDL-C are consequences 
of IR which could  lead to hypogonadism (Davies et al., 
2010). 
The objective of this study is to investigate biochemical 
parameters in relation to ED in type 2 DM patients, 
evaluate the presence of obesity and IR in type 2 DM 
patients, determination of testosterone level and its 
relationship with obesity and IR, and determine the 
relationship between the duration of type 2 DM and the 
levels of FBG and testosterone. This study is the first to 
investigate glucose, HbA1c, insulin, testosterone and lipid 
profile levels in blood and its relation to ED in type 2 DM 
patients in Gaza City-Palestine. 
 
 
MATERIALS AND METHODS 
 
This study is case control one which was conducted in Gaza 
city-Palestine from April to October, 2013.  
 
Inclusion criteria (for cases and controls) 
 
A total of 160 males aged 35 – 60 years were recruited 
for this study; 80 type 2 DM patients were recruited by 
consultant physicians from the diabetes clinic in Primary 
Health Care Centers (Al-remal and Sabha clinic). While 
an apparently healthy 80 eugonadal (testosterone level 
>3.0 ng/ mL), non-diabetic male subjects were recruited 
as controls. 
 
Exclusion criteria (controls) 
 
Fasting blood glucose (FBG), insulin, HbA1c, lipid profile 
and testosterone levels were determined to exclude type 
2 DM and ED. 
 
Characteristics of the subjects 
 
Demographic indices (age, parity, duration of diabetes 





questionnaires (face to face interview). Sexual   
characteristics (libido, ED, and NEME) were recorded 
through questionnaires using international index for 
erectile function (IIEF-5) scores. Anthropometric indices 
(weight and height) were measured using DETECTO 
Scale (USA). Body mass index (BMI) was calculated 
according to the following formula:  
 






10 ml of venous blood were collected aseptically by vein 
puncture from each subject in morning (8:00 – 10:00 AM) 
while fasting for at least 12 h, 3 mL of the blood were 
collected and placed in vacuum blood collection tube 
containing ethylene-di-amine tetra acetic acid (EDTA.K3) 
as anticoagulant for the determination of HbA1c. The 
remaining 7 mL of blood were delivered into vacuum 
blood collection tube without additives, samples were 
allowed to clot at room temperature for 15 min and serum 
was separated after centrifugation at 5000 rpm for 10 min 
using Thermo Scientific HERAEUS LABOFUGE 200 
Centrifuge. Serum was analyzed for the determination of 
glucose, total cholesterol, triglycerides, and HDL-C, 
insulin and testosterone levels. LDL-C was calculated by 
using Fried Wald's formula (Friedewald et al., 1972). An   
homeostasis model assessment for insulin resistance 
(HOMA-IR) index was calculated according to the formula 
of HOMA-IR calculator version 0.3 
http://www.hcvsociety.org/files/HOMACalc.htm, where IR 
was defined as a HOMA-IR of 3.0 or greater. All 
biochemical tests were carried out at Nebras Medical 
Laboratory, Gaza -Palestine. A written permission was 
obtained from the local Helsinke committee for the 
purpose of observing ethical considerations. Statistical 
package for social sciences (SPSS) software version 18 





Age and body mass index of subjects 
 
Table 1 compares the mean ± SD of age and BMI in type 
2 DM patients and controls. The mean age was the same 
in both type 2 DM and control subjects, (50.73 ± 7.13) 
years, as controls were selected and matched with cases 
according to age. Type 2 DM patients are presented with 
statistically significant higher BMI (P < 0.05) than controls 
(31.28 ± 6.43 vs. 27.41 ± 3.44). 
 
Comparison of biochemical indices among type 2 DM 
patients and controls 
 
Table 2 shows the mean values of FBG, cholesterol, 
triglycerides,     HDL-C,      LDL-C,      HbA1c,      insulin,  




Table 1. Age and BMI of type 2 DM patients and controls. 
 
 Participant N Mean SD SE P - value 
Age Type 2 DM 80 50.7375 7.13299 0.79749  
1.00 Control 80 50.7375 7.13299 0.79749 
BMI Type 2 DM 80 31.2888 6.43869 0.71987  
0.000
* 
Control 80 27.4100 3.44944 0.38566 
 
N = number of subjects, SD = Standard deviation, SE = Standard error, P = 
probability, 
*





Table 2. Comparison of biochemical indices among Type 2 DM patients and 
controls. 
 
 Type 2 DM (N = 80) Control (N = 80) P-value 
Mean ± SD Mean ± SD 
FBG (mg/dL) 202.1 ± 87.0 80.3 ± 10.8 0.000
*
 
HbA1c (%) 9.2 ± 1.7 5.7 ± 0.4 0.000
*
 
Insulin level (µIU/mL) 25.7 ± 38.5 12.8 ± 6.6 0.004
*
 
HOMA-IR 13.4 ± 23.9 2.5 ± 1.4 0.000
* 
Cholesterol (mg/dL) 203.6 ± 51.2 195.7 ± 36.0 0.258 
Triglycerides (mg/dL) 198.8 ± 76.1 160.2 ± 65.6 0.001
*
 
HDL-C (mg/dL) 37.5 ± 9.4 40.7 ± 8.2 0.022
*
 
LDL-C (mg/dL) 126.5 ± 47.1 122.1 ± 35.5 0.511 




HOMA-IR = Homeostasis Model Assessment – Insulin Resistance, FBG = Fasting 
blood glucose, HDL-C = High density lipoprotein-cholesterol, LDL-C = Low density 
lipoprotein-cholesterol, HbA1c = Glycohemoglobin A1c, N = number of subjects, SD 
= Standard deviation, SE = Standard error, P = probability, 
*
 = Significant, Type 2 




testosterone, and HOMA-IR among subjects. 
Comparison shows a statistically significant difference in 
FBG, triglycerides, HDL-C, HbA1c, insulin level, 
testosterone, and HOMA-IR. Significantly higher FBG, 
triglycerides, HbA1c, insulin level, and HOMA-IR (P < 
0.05) were observed in type 2 DM patients. However, 
significantly lower HDL-C and testosterone (P < 0.05) 
were observed in the same group. There was no 
significant difference in cholesterol and LDL-C between 
type 2 DM patients and controls (P > 0.05). 
 
Correlation of biochemical indices in type 2 DM 
patients 
 
Table 3 shows the correlations among biochemical 
indices.  FBG was correlated positively and significantly 
with HbA1c, and HOMA-IR (P < 0.05). In addition, insulin 
level was directionally and significantly correlated with 
HOMA-IR, (P < 0.05). Cholesterol was significantly 
correlated with triglycerides and LDL-C in the positive 
direction (P < 0.05). In addition, there was a significant 
positive correlation of triglycerides with LDL-C, but 
inversely with HDL-C (P < 0.05). All other correlations 
were not significant (P > 0.05). 
In addition, Table 3 shows that HbA1c was correlated 
significantly with BMI, and duration of type 2 DM in the 
positive direction (P < 0.05). Insulin level was correlated 
positively and significantly with BMI, also HOMA-IR was 
correlated positively and in a significant manner with BMI 
(P < 0.05). In addition, cholesterol was significantly 
correlated with duration of type 2 DM in a positive 
direction (P < 0.05). However, there was a significant 
positive correlation of triglycerides with BMI (P < 0.05). 
LDL-C was positively and significantly correlated with 
duration of type 2 DM (P < 0.05). All other correlations 
were not significant (P > 0.05). 
 
Relationship of anthropometric and demographic 
indices with testosterone in subjects 
 
Table 4 shows that there was a significant negative 
correlation between testosterone and BMI (p < 0.05). 
Also, in type 2 DM patients a negative significant 
correlation was found between testosterone and duration 
of type 2 DM (p < 0.05). In addition, for control group 
testosterone was correlated positively and significantly 
with sport practicing (p < 0.05). All other correlations were 
not significant (p > 0.05). 




Table 3. Correlation of biochemical indices (lipids profile, FBG, HbA1c, insulin level, and HOMA-IR) with anthropometric indices in 
Type 2 DM patients. 
 
Indices  FBG HbA1c Insulin level HOMA-IR Cholesterol Triglycerides HDL-C LDL-C 




0.125 0.138 0.048 0.081 
P-Value - 0.004 0.544 0.016 0.269 0.222 0.669 0.473 
HbA1c (N=80) R 0.323
* 
1.0 -0.100 -0.090 0.059 0.156 -0.140 0.040 
P-Value 0.004 - 0.377 0.428 0.601 0.168 0.214 0.724 
Insulin 
Level (N=80) 
R 0.069 -0.100 1.0 0.941
*
 0.160 0.080 -0.044 0.157 
P-Value 0.544 0.377 - 0.000 0.156 0.482 0.697 0.165 
HOMA 
-IR (N=80) 
R 0.269* -0.090 0.941
* 
1.0 0.169 0.088 -0.036 0.162 
P-Value 0.016 0.428 0.000 - 0.135 0.436 0.752 0.152 
Cholest-erol 
(N=80) 





P-Value 0.269 0.601 0.156 0.135 - 0.000 0.613 0.000 
Triglyc-erides 
(N=80) 






P-Value 0.222 0.168 0.482 0.436 0.000 - 0.000 0.035 
HDL-C (N=80) R 0.048 -0.140 -0.044 -0.036 -0.057 -0.502
* 
1.0 -0.100 
P-Value 0.669 0.214 0.697 0.752 0.613 0.000 - 0.378 





P-Value 0.473 0.724 0.165 0.152 0.000 0.035 0.378 - 









P-Value 0.865 0.022 0.018 0.011 0.109 0.007 0.242 0.266 
Duration of  Type 







P-Value 0.340 0.001 0.934 0.790 0.012 0.848 0.803 0.004 
 
FBG = Fasting blood glucose, HbA1c = Glycohemoglobin A1c, HOMA-IR = Homeostasis model assessment – Insulin resistance, HDL-C = 














Type 2 DM 
(N = 80), (r, P – Value) 
Control 
(N = 80), (r, P – Value) 
 NEME 0.052, 0.650 -0.204, 0.069 
Duration of Type 2 DM -0.209, 0.032
* 
- 






Age 0.024, 0.831 -0.131, 0.246 




NEME = Nocturnal/Early morning erection, Type 2 DM = Diabetes mellitus type 









Relationships of biochemical, anthropometric and 
demographic indices with ED and NEME in type 2 DM 
 
In type 2 DM patients, there was a significant positive 
correlation between ED and cholesterol, triglycerides, 
and LDL-C respectively (p < 0.05), but there was a 
significant correlation between ED and HDL-C in the 
negative direction (p < 0.05). Correlation of other indices 
was not significant (P > 0.05). In addition, there was no 
statistically significant correlation between NEME and 
biochemical indices (p > 0.05) (Table 5). 
In men with type 2 DM, there was a significant positive 
correlation of ED with duration and complications (mainly 
retinopathy) of type 2 DM (p < 0.05). Correlation of other 
indices were not significant (p > 0.05). However, NEME 
was correlated significantly but inversely with age and 





Sexual health may be a window into men’s health. 
Testosterone plays a critical role in male reproductive 
and metabolic functioning as well as improving life 
quality. Low testosterone is associated with a variety of 
comorbidities, including type 2 DM, IR, obesity, MS, and  




Table 5. Correlation of biochemical indices, anthropometric and demographic indices 





Type 2 DM 
(N = 80), (r, P – Value) 
Type 2 DM 
(N = 80), (r, P – Value) 
FBG -0.139, 0.109 -0.041, 0.717 
Cholesterol 0.365, 0.001
*









 -0.173, 0.125 
HbA1c 0.141, 0.105 -0.052, 0.649 
Insulin level 0.012, 0.458 0.022, 0.844 
HOMA-IR -0.028, 0.401 0.045, 0.690 
Testosterone 0.009, 0.470 0.052, 0.650 
Age 0.075, 0.254 -0.230, 0.040
*
 
BMI 0.040, 0.361 -0.054, 0.633 





Complications of Type 2 DM 0.272, 0.015
*
 -0.013, 0.910 
 
ED = Erectile dysfunction, NEME = Nocturnal/Early morning erection, FBG = Fasting 
blood glucose, HDL-C = High density lipoprotein-cholesterol, LDL-C = Low density 
lipoprotein-cholesterol, HbA1c = Glycohemoglobin A1c, HOMA-IR = Homeostasis model 










CVD (Rice et al., 2008). The prevalence of 
hypogonadism increases with age, and most men 
diagnosed with type 2 DM are older than 40 years. 
However, it remains unclear whether decreased 
testosterone levels are related to aging or diabetes and 
its complications (Ding  et  al.,  2006;  Corona  et  al.,  
2006; and Selvin  et  al.,  2007). In the present study, 
testosterone was significantly lower in type 2 DM patients 
compared with control group (p < 0.05). The mean age of 
type 2 DM patients and controls was the same (50.73 ± 
7.132 years), which mean that the observed low  
testosterone in this study may be attributed to type 2 DM, 
and its complications, as all subjects had the same age. 
In addition, a high percentage (67.5 %) of type 2 DM 
patients did not experience NEME. Although NEME 
decreases by age, there was a negative correlation 
between NEME and duration of type 2 DM (p < 0.05) that 
could be attributed to the decreased level of testosterone 
among type 2 DM patients. 
Testosterone levels vary inversely with waist 
circumference and BMI in men with MS. Contrarily, a 
direct and significant relationship was observed between 
BMI and testosterone in men with type 2 DM (Davies et 
al., 2010). Another study evaluated the effect of obesity 
on serum testosterone levels and penile duplex 
ultrasonography variables in men with ED, obesity was 
associated with lower testosterone levels and 
disturbances of penile haemodynamics (Zohdy et al., 
2007). According to the present results, prevalence of 
high BMI and obesity was significantly higher in type 2 
DM patients compared with controls (p < 0.05). In 
addition, testosterone was correlated significantly but 
inversely with BMI (p < 0.05). This could be attributed to 
the difference in the mean BMI for type 2 DM patients in 
Palestinian people compared to other populations. 
However, BMI correlated significantly and positively with 
HbA1c, insulin level, HOMA-IR, and triglycerides (p < 
0.05). These correlations may be due to uncontrolled 
diabetes, which was observed clearly by the high level of 
FBG and HbA1c in type 2 DM patients compared with 
controls. In addition, high calorie diet and sedentary life 
style which lead to obesity and may cause hypogonadal 
state that disrupts the endocrine system, as its normal 
function is critical for maintaining erection. 
Bansal et al. (2005) evaluated the prevalence of IR, 
measured by the quantitative insulin sensitivity check 
index, in 154 men with ED. They reported a 79.2% 
incidence of IR in patients with ED but without comparing 
them with a control group, and a negative correlation was 
observed between HOMA and international index for 
erectile function (IIEF-5). In the present study, a 
statistically significant higher degree of IR in type 2 DM 
patients was found compared with controls (p < 0.05). In 
addition, a positive statistically significant correlation 
between BMI and HOMA-IR was observed (p < 0.05). 
However, the observed results coincided with those of 
Bansal et al. (2005) regarding the high incidence of IR 
among diabetic ED patients, which in our study could be 
attributed to high prevalence of BMI and long duration of 
type 2 DM, as 44 (55%) of type 2 DM patients have had 
the disease for more than eight years. 
Among patients with ED, type 2 DM  is  associated  with 




hypogonadism, at least in the 6
th
 decade (Corona et al., 
2004). The reduction of total testosterone in type 2 DM 
patients could be theoretically due to a reduction of sex 
hormone binding globulin (Van Dam et al., 2003). In fact, 
among those patients in whom measurements of free 
testosterone were available, diabetes was associated 
with low hormone levels (Corona et al., 2006). The 
present finding indicates that duration of type 2 DM was 
correlated significantly but inversely with testosterone (p 
< 0.05), which affirm the hypothesis of increased 
prevalence of ED in type 2 DM patients due to the high 
prevalence of low testosterone in type 2 DM patients than 
in control group. 
Dyslipidemia characterizes individuals with MS and 
type 2 DM (Ashraf –Sohail et al., 2006). In hypogonadal  
men  with type 2 DM, testosterone was correlated  
negatively with  total  cholesterol,  but  had  no  effect  on  
other components  of  the  lipid  profile (Malkin  et  al.,  
2004). While  others  found  a  positive  association 
between  HDL-C  and  testosterone (Roger  et al., 2007 
and Stanworth  et  al.,  2007). In the present study, there 
was no correlation between testosterone and lipid profile 
among type 2 DM patients (p > 0.05), this could be 
attributed to small sample size in this study. In addition, 
cholesterol and LDL-C were correlated positively and 
significantly with duration of type 2 DM, but testosterone 
was correlated inversely and significantly with duration of 
type 2 DM and BMI (p < 0.05), this could be explained on 
the basis that long duration of type 2 DM and prolonged 
elevation of glucose may lead to IR and dyslipidemia 
which in turn causes reduced utilization of glucose by 
pituitary gland cells. Pituitary dysfunction leads to 
decreased secretion of LH and FSH which control 
testosterone secretion. However, ED was correlated 
significantly and positively with cholesterol, triglycerides, 
and LDL-C, but inversely with HDL-C (p < 0.05). These 
results coincide with previous studies in that dyslipidemia 
is a risk factor of ED and is linked to it. In addition, ED 
was correlated with duration of type 2 DM and its 
complications (p < 0.05), this may be attributed to 
endothelial dysfunction which characterizes diabetic 
patients. 
In a study of Sharifi et al. (2012), they found that age and 
administration of calcium channel blockers in type 2 DM 
men were the only independent predictors of ED, while 
other previously published risk factors including BMI, 
blood pressure, HbA1c, impaired lipid profile, high 
creatinine, testosterone level, and even history of 
smoking did not have predictive value for ED risk in type 
2 DM patients (Sharifi et al., 2012). On the other hand, 
other studies reported that long duration of type 2 DM 
and poorer glycemic control in diabetic men were 
significant predictors of ED (Mijares et al., 2010; Yang et 
al., 2010; and Giugliano et al., 2010). However, other 
studies reported no correlation between ED and BMI 
(Ziaei-Rad et al., 2010). In the present study, duration of 





predictor risk factors associated with ED (P < 0.05). Data 
is not shown.  
Incidence of low testosterone in the present study was 
higher in type 2 DM patients than controls. As a result ED 
is common among type 2 DM patients and they probably 
were affected earlier than non-diabetic men. In addition, 
low testosterone among type 2 DM patients may be a 
result of increased prevalence of obesity. Increased 
prevalence of IR among type 2 DM patients could lead to 
decreased glucose uptake by the pituitary and gonads 
leading to hypogonadism and low testosterone level. 
High incidence of dyslipidemia among type 2 DM patients 
is considered as one of the important risk factors that 
increases incidence of ED. Long duration of type 2 DM 
and prolonged elevation of glucose lead to IR, 
dyslipidemia, and low testosterone level. In addition, high 
level of blood glucose and long duration of type 2 DM, in 
addition to low testosterone level were determined to be 
of the leading independent predicting risk factors 
associated with ED. 
It is recommended to inform type 2 DM patients with its 
complications including ED, and provide relevant 
information, and increase clinician awareness of the need 
to address men’s sexual health and implement 
appropriate strategies. Continuous monitoring of FBG, 
HbA1c, testosterone, and lipid profile for type 2 DM 
patients for the purpose of early detection of ED. 
Restricted diet and changing life style in addition to 
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